GlassScriptPhysician profile
Steven R Corwin
NPI 1720089964
$5,670.48
in general payments reported to CMS, 2019-2025
22 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $568 · 2021: $661 · 2022: $396 · 2023: $427 · 2024: $958 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $703.60 | 2019-2025 | Clareon Panoptix Pro, Clareon, Rocklatan |
| Novartis Pharmaceuticals Corporation | $640.98 | 2019-2023 | |
| Glaukos Corporation | $595.18 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $524.18 | 2019-2024 | Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $429.10 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $396.09 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $338.75 | 2019 | |
| Allergan, INC. | $328.41 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $313.24 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Nova Eye, INC. | $284.20 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.82 | 2019-2021 | |
| Oyster Point Pharma, INC. | $192.94 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $192.85 | 2022-2025 | Oxervate |
| Abbvie INC. | $120.47 | 2022-2024 | |
| Harrow Eye, LLC | $102.26 | 2024-2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $89.38 | 2019-2021 | |
| Sight Sciences, INC. | $51.93 | 2020-2021 | |
| Biotissue Holdings INC. | $40.12 | 2023-2024 | |
| Kala Pharmaceuticals, INC. | $34.38 | 2019-2020 | |
| Horizon Therapeutics Plc | $24.06 | 2022 | |
| Rxsight INC | $15.73 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Akorn Operating Company LLC | $14.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Corwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.